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ABSTRACT 
Objectives: Influenza virus infections can cause severe acute lung injury leading to significant morbidity and 
mortality. Thioredoxin-1 is a redox-active defensive protein induced in response to stress conditions. Animal 
experiments have revealed that thioredoxin-1 has protective effects against various severe disorders. This 
study was undertaken to evaluate the protective effects of recombinant human thioredoxin-1 (rhTRX-1) 
administration on influenza A virus (H1N1)-induced acute lung injury in mice. 
Design: Prospective animal trial. 
Setting: Research laboratory. 
Subjects: Nine-week-old male C57BL/6 mice inoculated with H1N1. 
Intervention: The mice were divided into vehicle-treated group and rhTRX-1-treated group. For survival 
rate analysis, the vehicle or rhTRX-1 was administered intraperitoneally every second day from Day -1 to 
Day 13. For lung lavage and pathological analyses, vehicle or rhTRX-1 was administered intraperitoneally 
on Day -1, 1, and 3. 
Measurements and Main Results: Lung lavage and pathological analyses were performed at 24, 72, and 120 
hr after inoculation. The rhTRX-1 treatment significantly improved the survival rate of H1N1-inoculated 
mice, although the treatment did not affect virus propagation in the lung. The treatment significantly 
attenuated the histological changes and neutrophil infiltration in the lung of H1N1-inoculated mice. The 
treatment significantly attenuated the production of TNF-α and CXCL1 in the lung and oxidative stress 
enhancement which were observed in H1N1-inoculated mice. H1N1 induced expressions of TNF-α and 
CXCL1 in murine lung epithelial cells MLE-12, which were inhibited by the addition of rhTRX-1. The 
rhTRX-1 treatment started 30 min after H1N1 inoculation also significantly improved the survival of the 
mice. 
Conclusions: Exogenous administration of rhTRX-1 significantly improved the survival rate and attenuated 
lung histological changes in the murine model of influenza pneumonia. The protective mechanism of TRX-1 
might be explained by its potent antioxidative and anti-inflammatory actions. Consequently, rhTRX-1 might 
be a possible pharmacological strategy for severe influenza virus infection in humans. 
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Influenza virus infections cause a broad array of illnesses that are responsible for significant morbidity 
and mortality both in children and adults on a yearly basis (1). Influenza can cause periodic global 
pandemics with even higher penetrance of illness. Highly pathogenic avian influenza virus H5N1 emerged in 
1996 in Hong Kong, China (2). Although cases of avian influenza infections have decreased since 2006, the 
emergence of a pandemic strain remains a threat. In 2009, novel swine-origin influenza virus H1N1 was 
identified in Mexico. It continues to spread globally (3). 
Several antiviral compounds have been developed against influenza virus to interfere with specific events 
in the replication cycle. Under treatment with these drugs, however, influenza virus infection occasionally 
causes severe pneumonia, necessitating intensive care and mechanical ventilation in the clinical settings. The 
course of illness and complications might also be affected by coexisting pathologies. The discovery of a 
novel anti-influenza therapeutic approach would increase the effectiveness of traditional virus-based 
strategies (4). 
Reactive oxygen species (ROS) such as superoxide (O2-), hydroxyl radical (OH), and nitric oxide (NO) 
represent an important component of the host’s arsenal to combat invading microorganisms, but ROS present 
significant immunopathology to surrounding tissues because of their toxicity and lack of specificity (5, 6). It 
is recognized that much of the oxidative injury associated with simultaneous production of O2- and NO is 
mediated by a strong oxidant: peroxynitrite (ONOO-) (7). The pathogenesis of influenza pneumonia is almost 
certain to involve not only apoptotic cell death mediated through viral replication in the infected cells, but 
also the injury of not-infected cells by ROS derived from infiltrating neutrophils and macrophages and 
respiratory tract epithelium (4). A critical role of ROS as mediators of influenza virus-induced lung injury is 
supported by previous studies. In murine models of influenza pneumonia, excessive generation of ROS 
contributed to lung injury in infected animals; treatment with superoxide dismutase, catalase (antioxidative 
enzymes), N-monomethyl-L-arginine (NO synthase inhibitor) or allopurinol (xanthine oxidase inhibitor) and 
overexpression of extracellular superoxide dismutase or heme oxygenase-1 suppressed lung injury and 
inflammation and improved the survival rate (8-13). Moreover, virus-infected selenium-deficient mice 
developed more severe influenza pneumonia than did selenium-adequate mice, implying the importance of 
selenium-dependent glutathione peroxidase and thioredoxin reductase (antioxidative enzymes) for protection 
against influenza virus-induced inflammatory processes (14). 
Thioredoxin-1 (TRX-1), a redox-active small protein that is ubiquitous in the body, is a defensive protein 
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that is induced in response to various stress conditions (15). In addition to its antioxidative effect by 
dithiol-disulfide exchange in its active site, TRX-1 has anti-inflammatory and antiapoptotic effects (15, 16). 
Human TRX-1-overexpressing transgenic mice survive longer and are more resistant to various oxidative 
and inflammatory conditions than control mice are (15, 17). Of greater importance is the fact that TRX-1 
overexpression is also effective in augmenting the host defense against influenza pneumonia, thereby 
reducing mortality (18). Overexpression of TRX-1 might modulate the ROS generation induced by influenza 
virus infection and regulate the redox-dependent signal transductions in the host defense responses against 
influenza virus infection. 
These findings prompted us to evaluate the protective effects of recombinant human thioredoxin-1 
(rhTRX-1) administration on acute lung injury in mice with influenza pneumonia. If rhTRX-1 administration 
can produce significant beneficial effects, then its clinical efficacy for treating severe pneumonia will be 
highly anticipated. This study demonstrated for the first time that rhTRX-1 administration decreases the 
mortality rate and ameliorates acute lung injury in influenza A virus (H1N1)-infected mice, possibly through 
its antioxidative and anti-inflammatory actions. 
 
MATERIALS AND METHODS 
This study was approved by the Animal Use Committee of Okayama University Graduate School of 
Medicine, Dentistry and Pharmaceutical Sciences and was conducted in accordance with National Institutes 
of Health Guidelines. 
Experimental Animals 
Eight-week-old male C57BL/6 mice (21-24 g body weight) were purchased from Charles River 
Laboratories Japan Inc. (Yokohama, Japan). They were housed in the specific-pathogen-free animal facility 
at 25°C with a 12-hour light/dark cycle. They were fed a standard diet (Oriental MF; Oriental Yeast Co., Ltd., 
Tokyo, Japan). 
Regional Distribution of TRX-1 mRNA 
Nine-week-old mice were anesthetized by intraperitoneal injection of ketamine (50 mg/kg) and 
pentobarbital (30 mg/kg). The brain, lung, liver, kidney, and spleen were removed and soaked in RNAlater 
(Applied Biosystems, Foster City, CA). Total RNA was extracted using RNeasy Plus Mini (Qiagen Inc., 
Hilden, Germany). Two micrograms of total RNA was reverse-transcribed to cDNA using RETROscript 
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(Applied Biosystems). Reverse-transcribed samples were analyzed for murine TRX-1 and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific cDNA by PCR amplification using the 7500 
Real-Time PCR System (Applied Biosystems). The PCR primers were designed according to the protocol 
described by Sigma-Aldrich Japan (Tokyo, Japan) (Table 1). 
Production of Influenza Virus Pneumonia 
Influenza virus A/Puerto Rico/8/34 (H1N1) was used throughout the experiments. The virus was 
propagated in 10-day-old embryonated chicken eggs. The virus titer was quantitated by plaque assay using 
Madin-Darby canine kidney cells. Nine-week-old mice were anesthetized by intraperitoneal injection of 
ketamine and pentobarbital, as described above. Then they were inoculated intranasally with H1N1 
suspended in 25-μl sterile phosphate-buffered saline (PBS). The doses of influenza virus were 300 
plaque-forming units for survival rate analysis and 1000 plaque-forming units for lung lavage and 
pathological analyses. The animals were allowed to recover thereafter. The day of virus inoculation was 
defined as Day 0. 
Administration of rhTRX-1 
Recombinant human thioredoxin-1 was supplied by Redox Bio Science Co., Ltd. (Kyoto, Japan). The 
quality and purity of the rhTRX-1 used for the present experiments were approved by Pharmaceuticals and 
Medical Devices Agency in Japan, which is equivalent to the FDA in the United States. Its safety and 
kinetics were established in preclinical studies using animal models (15). 
In preliminary experiments, 9-week-old mice were administered rhTRX-1 intraperitoneally (40 μg in 
100-μl PBS) and at 0 hr (untreated), 1, 3, or 6 hr after administration (3-6 mice at each time point) they were 
anesthetized and blood and the left lung were sampled for measurement of rhTRX-1 using a sandwich 
ELISA kit (Redox Bio Science Co., Ltd.) (15, 19). The ELISA did not cross-react with murine TRX-1. The 
lung tissues were homogenized in 1 ml of lysis buffer. The concentrations in the sera and the lung 
homogenate supernatants at 0, 1, 3, and 6 hr after the rhTRX-1 administration were, respectively, <0.5, 
1237±298, 97±23, and 18±3 ng/ml (sera) and <0.5, 62±21, 20±10, and 20±9 ng/ml (lung tissues). In 
accordance with our previous work (19), a bolus intraperitoneal injection of 40 μg of rhTRX-1 led to 
systemic delivery and lung deposition in mice. 
Murine TRX-1 mRNA Expression in the Lung after rhTRX-1 Administration 
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A group of 9-week-old mice were administered rhTRX-1 intraperitoneally (40 μg in 100-μl PBS). At 0 
hr (untreated), 1, 3, or 6 hr after rhTRX-1 administration, the mice were anesthetized and the left lung was 
sampled for analysis of murine TRX-1 and GAPDH mRNA expression as described above (3-5 mice at each 
time point). 
Treatment with rhTRX-1 for H1N1-Inoculated Mice 
The C57BL/6 mice were divided randomly into a vehicle-treated group (control group) and an 
rhTRX-1-treated group (treatment group). 
Survival rate analysis: The vehicle (100-μl PBS) or rhTRX-1 (40 μg in 100-μl PBS) was administered 
intraperitoneally every second day from Day -1 (the day before H1N1 inoculation) to Day 13 (10 mice per 
group). Survival was observed until Day 14. No other parameter was measured in these mice. 
Lung lavage and pathological analyses: The vehicle (100-μl PBS) or rhTRX-1 (40 μg in 100-μl PBS) 
was administered intraperitoneally on Day -1, 1, and 3. Lung lavage and pathological analyses were 
performed on Day 1 (24 hr), 3 (72 hr), and 5 (120 hr) after H1N1 inoculation (5 mice per group at each time 
point). 
Lung Lavage Analysis 
The mice were anesthetized by intraperitoneal injection of ketamine and pentobarbital as described 
above. Blood was sampled for measurement of hydroperoxides (described below). Then the left lung hilus 
was ligated and the right lung was lavaged twice with 500-μl cold Hanks’ balanced salt solution through a 
20-gauge cannula. The recovered lavage was collected and centrifuged at 2000 rpm for 10 min at 4°C and 
the supernatant was stored at -80°C for measurement of cytokines (described below). The total cell number 
in the lavage fluid was calculated from the cell number in the 200-μl sediment. Cell differentiation was 
examined using Diff-Quick staining (Dade Behring Inc., Newark) for at least 200 cells on a smear prepared 
from the sediment. The percentage of neutrophils was determined. The total neutrophil number in the lavage 
fluid was calculated and expressed per animal. 
Lung Pathological Analysis 
The upper portion of the left lung was fixed in buffered 4% paraformaldehyde solution and then 
embedded in paraffin. Sections (4-μm slices) including a cut at the hilus were stained with hematoxylin and 
eosin for light microscopy. The histological examination procedure was similar to that described by Xu et al. 
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(20). Four readily identifiable pathological processes were graded semiquantitatively on a scale of 0 to 4: 
alveolar and interstitial edema, hemorrhage, margination and infiltration of inflammatory cells, and 
formation of bronchiolitis: a score of 0 represented normal lung; 1 represented mild; 2 was moderate; 3 was 
severe; and 4 denoted very severe changes. For each mouse, the lung injury score was calculated by adding 
the individual grades (the mean value for four sections) for each category. The histology was reviewed by 
two of the authors (MY and AM) in a blinded manner. The middle portion of the left lung was excised and 
soaked in RNAlater. Total RNA was extracted and 1 μg of total RNA was reverse-transcribed to cDNA 
according to the procedure described above. The samples were analyzed for virus copies using the 7500 
Real-Time PCR System. The PCR primers were designed according to the protocol of Sigma-Aldrich Japan 
(Table 1).  
Immunohistochemical Study 
Immunohistochemical analysis was performed using the other upper lung sections (4-μm slices) that 
were obtained from vehicle-treated and rhTRX-1-treated mice on Day 3 (72 hr) after H1N1 inoculation. The 
lung sections obtained from 9-week-old non-virus-inoculated mice served as controls. Antibodies against 
granulocyte-differentiation antigen (Gr-1) (BioLegend, San Diego, CA) (21) and 
8-hydroxy-2’-deoxyguanosine (8-OHdG) (Japan Institute for the Control of Aging, Shizuoka, Japan) (22) 
were used respectively for detection of neutrophil infiltration and cellular DNA oxidation according to the 
manufacturers’ instructions. The results were evaluated by two of the authors (MY and AM) in a blinded 
manner. 
Measurement of Cytokines 
TNF-α, a proinflammatory cytokine, participates in important processes involved in the inflammatory 
response. CXCL1, a member of the CXC chemotactic cytokine family, plays a pivotal role in the activation 
and extravasation of neutrophils (23). Concentrations of TNF-α and CXCL1 were measured using sandwich 
ELISA methods in lung lavage fluids obtained from vehicle-treated and rhTRX-1-treated mice on Day 1 (24 
hr), 3 (72 hr), and 5 (120 hr) after H1N1 inoculation (5 mice per group at each time point). Those 
concentrations were also measured in the right lung homogenate supernatants obtained from the same mice 
on Day 3 (72 hr) (5 mice per group). The ELISA procedure was referred to that described by Matsukawa et 
al. (23). The captured antibodies, detection antibodies, and recombinant cytokines were purchased from 
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R&D Systems (Minneapolis, MN). The ELISAs used for this study did not cross-react with other available 
murine cytokines. They consistently detected cytokine concentrations higher than 10 pg/ml. 
Measurement of Serum Hydroperoxides 
Blood was sampled from vehicle-treated and TRX-treated mice on Day 1 (24 hr), 3 (72 hr), and 5 (120 
hr) after H1N1 inoculation (5 mice per group at each time point). Blood was also sampled from another 
group of 9-week-old non-virus-inoculated mice given vehicle (100-μl PBS) intraperitoneally 24 hr before 
(10 mice). Serum was prepared. The serum concentration of hydroperoxides (whole oxidant capacity of 
serum against N,N-diethylparaphenylene-diamine in acidic buffer) was measured using the Free Radical 
Analytical System (Diacron International, Grosseto, Italy) (24). The measurement unit was CARR U. It has 
been established that 1 CARR U corresponds to 0.08 mg/dl hydrogen peroxide (25). 
Cell Biological Study 
MLE-12 cells (ATCC, Manassas, VA), a SV40-transformed murine lung epithelial cell line, were grown 
to confluence in RPMI-1640 medium (Sigma-Aldrich Corp., St. Louis, MO) containing 10% fetal bovine 
serum (Gibco-BRL, Grand Island, NY). The MLE-12 cells were not inoculated or were inoculated with 
H1N1 (at multiplicity of infection of 10) for 6 hr. The H1N1-inoculated cells were not treated or were treated 
with rhTRX-1 (at doses of 10 or 100 ng/ml) simultaneously. Expression of TNF-α and CXCL1 mRNA was 
analyzed using reverse transcription and real-time quantitative PCR (ABI 7700 Sequence Detector System; 
Applied Biosystems), as described previously by Ito et al. (26). 
Treatment with rhTRX-1 after H1N1 Inoculation (Therapeutic Protocols) 
Other groups of 9-week-old mice were used in the therapeutic protocols. The dose of influenza virus was 
300 plaque-forming units. The intraperitoneal administration of vehicle (100-μl PBS) or rhTRX-1 (40 μg in 
100-μl PBS) was started 30 min (14 mice per group) or 4 hr (11 mice per group) after H1N1 inoculation 
(Day 0) and repeated every second day until Day 12. Survival was observed until Day 14. 
Statistical Analysis 
All data are expressed as mean±SEM and compared using unpaired t-test, or one-way ANOVA or 
two-way ANOVA followed by Bonferroni’s post-test where appropriate. Survival curves were analyzed using 
the Kaplan-Meier log-rank test. Differences for which p < 0.05 were considered significant. All statistical 
calculations were performed using GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA). 
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RESULTS 
Regional Distribution of mRNA Expression of TRX-1 
Figure 1A shows the mRNA expression of TRX-1 in normal mice for various organs. The level of 
TRX-1 expression in the lung was the highest: several times higher than that in the other organs including the 
brain, liver, kidney, and spleen. Results suggest that TRX-1 plays some physiologically important regulatory 
role in the animal lung. 
Murine TRX-1 mRNA Expression in the Lung after rhTRX-1 Administration 
Figure 1B presents changes of mRNA expression of TRX-1 in the lung of normal mice after rhTRX-1 
administration. The intrinsic mRNA expression of TRX-1 was suppressed in the lung after a bolus 
intraperitoneal injection of rhTRX-1 (40 μg). The suppressive effect was statistically significant at 1 hr and 3 
hr after the administration compared with the pretreatment level. 
Effects of rhTRX-1 on Survival Rate and Viral Load in the Lung after H1N1 Inoculation 
Comparison of survival curves using the Kaplan-Meier log-rank test showed a significant difference 
between the vehicle-treated group and the rhTRX-1-treated group (Fig. 2A). The rhTRX-1 treatment 
significantly improved the survival rate of H1N1-inoculated mice. All 10 control mice died from Day 7 to 
Day 9, but 4 (40%) of 10 rhTRX-1-treated mice survived over 14 days after H1N1 inoculation. Of note, all 
animals in both groups survived over 5 days (120 hr) after inoculation. All the mice that survived until Day 
14 recovered health thereafter. 
The viral load in the lung increased significantly from 24 hr to 72 hr after inoculation, decreasing 
thereafter in control mice (Fig. 2B). A similar tendency was observed in rhTRX-1-treated mice. The viral 
load in rhTRX-1-treated mice was almost comparable to that in control mice at each time point. These results 
indicate that rhTRX-1 treatment improves the survival rate of H1N1-inoculated mice significantly, although 
the treatment does not affect propagation of the influenza virus in the lungs of these animals. 
Effects of rhTRX-1 on Lung Histology after H1N1 Inoculation 
H1N1-inoculated control mice presented diffuse edema and inflammatory cellular infiltration in alveoli 
and interstitium of the lung, hemorrhage, and thickened airways at 72 hr after inoculation. The rhTRX-1 
treatment attenuated the histological changes in the lung (Fig. 3A). The lung injury score increased 
significantly from 24 hr to 72 hr and 120 hr in the control group (p < 0.01 at 24 hr vs. 72, 120 hr, one-way 
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ANOVA with Bonferroni’s post-test) (Fig. 3B). In the treatment group, the score increased significantly from 
24 hr to 72 hr (p < 0.05), but the score at 120 hr was not significantly different from that at 24 hr. The lung 
injury score remained significantly lower in rhTRX-1-treated mice than in control mice. These histological 
analyses indicate that rhTRX-1 treatment significantly attenuates the degree of acute lung injury in 
H1N1-inoculated mice. 
Effects of rhTRX-1 on Neutrophil Infiltration in the Lung after H1N1 Inoculation 
The neutrophil number in lung lavage fluid increased significantly from 24 hr to 72 hr after virus 
inoculation in control group (p < 0.01, one-way ANOVA with Bonferroni’s post-test). The neutrophil number 
at 120 hr was not significantly different from that at 72 hr (Fig. 4A). In the treatment group, the neutrophil 
number increased significantly from 24 hr to 72 hr and decreased significantly thereafter (p < 0.01 at 72 hr vs. 
24, 120 hr). The neutrophil number remained lowered in rhTRX-1-treated mice compared with control mice. 
The difference reached statistical significance at 72 hr and 120 hr after inoculation. Histologically, influenza 
virus inoculation increased neutrophil infiltration in the lung at 72 hr after inoculation. The rhTRX-1 
treatment almost reversed this effect (Fig. 4B). These results indicate that rhTRX-1 treatment significantly 
attenuates the neutrophil infiltration in the lung of H1N1-inoculated mice. 
Effects of rhTRX-1 on Cytokine Production in the Lung after H1N1 Inoculation 
The TNF-α and CXCL1 concentrations in lung lavage fluid were significantly lower in rhTRX-1-treated 
mice than in control mice at 72 hr after inoculation (Figs. 5A, 5B). In lung tissue analyses, both cytokine 
concentrations were lowered significantly by rhTRX-1 treatment at 72 hr after inoculation (Figs. 5C, 5D). 
These results indicate that rhTRX-1 treatment significantly attenuates the inflammatory cytokine production 
in the lung of H1N1-inoculated mice. 
Effects of rhTRX-1 on Oxidative Stress Markers after H1N1 Inoculation 
Histologically, H1N1 inoculation increased 8-OHdG formation in the lung at 72 hr after inoculation. The 
8-OHdG formation was observed primarily in infiltrating cells and occasionally in lung epithelial cells. The 
rhTRX-1 treatment almost reversed this effect (Fig. 6A). Serum concentration of hydroperoxides was 
significantly lower in rhTRX-1-treated mice than in control mice at 72 hr after inoculation (Fig. 6B). 
Concentrations at 24, 72, and 120 hr after inoculation in either group were significantly higher than that 
(122±6 CARR U) in non-virus-inoculated mice (p < 0.05 in each, unpaired t-test). These results indicate that 
rhTRX-1 treatment significantly attenuates the oxidative stress enhancement that is observed in 
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H1N1-inoculated mice. 
Effects of rhTRX-1 on Cytokine mRNA Expression in H1N1-inoculated MLE-12 Cells 
Expression of cytokine mRNA was analyzed by reverse-transcription PCR in MLE-12 cells. The TNF-α 
and CXCL1 mRNA accumulated significantly at 6 hr after inoculation (Figs. 7A, 7B). Simultaneous 
rhTRX-1 treatment (at doses of 10, 100 ng/ml) almost abolished this effect. These results indicate that 
rhTRX-1 treatment significantly attenuates the increase in cytokine mRNA expression in H1N1-inoculated 
murine lung epithelial cells. 
Treatment with rhTRX-1 after H1N1 Inoculation (Therapeutic Protocols) 
The rhTRX-1 treatment started 30 min after virus inoculation significantly improved the survival rate of 
H1N1-inoculated mice (p < 0.05 vs. control) (Fig. 8A). Only one of 14 control mice (7%) survived over 14 
days after H1N1 inoculation, but 6 (43%) of 14 rhTRX-1-treated mice survived. However, the rhTRX-1 
treatment started 4 hr after inoculation had no effect on the survival rate. None of 11 control mice and only 2 
(18%) of 11 rhTRX-1-treated mice survived more than 14 days after H1N1 inoculation (Fig. 8B). 
 
DISCUSSION 
Thioredoxin-1 is a ubiquitously expressed, multifunctional protein that has a redox-active 
dithiol-disulfide within the conserved -Cys-Gly-Pro-Cys- sequence. TRX-1 protects cells against oxidative 
stress by scavenging ROS in concert with peroxiredoxins and prevents cellular apoptosis by inhibiting 
apoptosis signal-regulating kinase 1 (15). Furthermore, TRX-1 suppresses inflammation by regulating 
neutrophil activation and extravasation and exerts the anti-inflammatory effect (15, 16). In the clinical field, 
extracellular concentrations of TRX-1 have been measured in various conditions characterized by oxidative 
stress and inflammation, including sepsis, viral infection, autoimmune disease, ischemia-reperfusion injury, 
and acute lung injury (27-30). These studies document that the TRX-1 concentrations are elevated in patients 
with these diseases and that they are correlated significantly with the activity of such diseases. 
Overexpression of human TRX-1 in transgenic mice induces resistance to harmful conditions, including 
ischemic brain damage, adriamycin-induced cardiotoxicity, ischemia-reperfusion renal injury, and 
cerulein-induced pancreatitis (31-34). More importantly, human TRX-1 transgenic mice are more resistant 
than control mice to proinflammatory cytokine-, bleomycin-, diesel exhaust particle-, or cigarette 
smoke-induced lung injury (19, 35, 36) and to influenza virus-induced pneumonia (18). Administration of 
 12
rhTRX-1 is also effective in animal models, especially for acute lung injury, including proinflammatory 
cytokine-, bleomycin-, or cigarette smoke-induced inflammatory injury, ovalbumin-induced airway 
hyperresponsiveness and inflammation, and lipopolysaccharide-induced bronchoalveolar neutrophil 
infiltration (19, 36-38). All these results demonstrate that TRX-1 has potent protective effects on oxidative 
stress-associated or inflammation-associated lung disorders in animals. 
Influenza virus infections are responsible for numerous pneumonia cases every year. In severe cases, 
they can cause death (1-3). Influenza virus causes death of infected cells by cytopathology. Furthermore, 
when the immune system responds to the infection exuberantly, additional lung damage and overwhelming 
systemic illness are likely to ensue. A marked increase in concern has occurred in relation to the possibility 
of future severe pandemics. Therefore, it is crucial to identify new therapeutic strategies for influenza (4). 
This study demonstrated, for the first time, the protective effects of rhTRX-1 administration in a murine 
model of acute lung injury induced by influenza virus infection. Intranasal instillation of influenza A virus 
(H1N1) was used to produce viral pneumonia in this model. Every second day, 40 μg of rhTRX-1 was 
administered intraperitoneally. At the beginning of the study, we examined the regional distribution of 
mRNA expression of TRX-1 in normal mice. We found that TRX-1 expression was at the highest level in the 
lung. Results suggest that the endogenous TRX-1 system plays some physiologically important regulatory 
role in the lung and that lung disease might be a target for this protein (15). Results also show that the TRX-1 
expression in the lung was suppressed significantly after intraperitoneal injection of rhTRX-1. 
Administration of rhTRX-1 producing elevated blood concentrations (mean: 1237 ng/ml), which are about 
10 times higher than those in oxidative and inflammatory disorders in humans (40-140 ng/ml) (15), is likely 
to suppress the endogenous TRX-1 system in the animal lung. 
Intraperitoneal administration of rhTRX-1 significantly improved the survival rate of H1N1-inoculated 
mice. The viral load in the lung increased from 24 hr to 72 hr after inoculation, confirming the occurrence of 
influenza pneumonia in both vehicle-treated (control) and rhTRX-1-treated mice. Notably, the viral load in 
rhTRX-1-treated mice was almost comparable to that of control mice at each time point of the study. The 
rhTRX-1 treatment did not affect propagation of influenza virus in the animal lung. The result is consistent 
with previous reports in which administration of N-monomethyl-L-arginine, overexpression of extracellular 
superoxide dismutase or adenovirus-mediated transfer of heme oxygenase-1 was used as a therapeutic tool 
against influenza pneumonia in mice (10-12). The occurrence of influenza pneumonia was documented 
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histologically in mice subjected to H1N1 inoculation in this study. The H1N1-inoculated control mice 
presented characteristic changes of acute lung injury: diffuse edema and inflammatory cellular infiltration in 
alveoli and interstitium of the lung, hemorrhage, and thickened airways (20). Particularly, the lung injury 
score remained at high levels at 24, 72, and 120 hr after inoculation. The rhTRX-1 treatment attenuated the 
histological changes and the lung injury score, confirming histologically that rhTRX-1 ameliorates 
H1N1-induced pneumonia in mice. 
Previous studies revealed that influenza virus infection caused a marked increase in the cell number in 
lung lavage fluid, and demonstrated that this increase primarily reflected an increase in neutrophils and 
macrophages (9-12). In this study, we measured the neutrophil number in lung lavage fluid obtained from the 
animals. In control mice, the neutrophil number increased from 24 hr to 72 hr and remained high at 120 hr. 
The rhTRX-1 treatment suppressed the increase in neutrophils. Histological examination revealed much less 
neutrophil infiltration to lung parenchyma in rhTRX-1-treated mice. Accumulation of activated neutrophils 
in the lung is an early critical step in the inflammatory process of acute lung injury. According to our 
previous studies (15, 16, 34, 36, 38), elevated levels of circulating TRX-1 effectively suppress neutrophil 
extravasation into sites of inflammation. The protective effects of rhTRX-1 on H1N1-induced pneumonia are 
partly attributed to its antichemotactic action for neutrophils. 
Increased synthesis and secretion of inflammatory mediators contribute to the overall pathology of lung 
injury. Several cytokines apparently play crucial roles in the acute and uncontrollable inflammatory process 
of influenza pneumonia (1, 2, 4, 39, 40). In this study, we measured TNF-α (a proinflammatory cytokine) 
and CXCL1 (a CXC chemotactic cytokine) concentrations in lung lavage fluid at 24, 72, and 120 hr after 
inoculation and lung homogenate supernatants at 72 hr. The rhTRX-1 treatment suppressed the 
concentrations of these cytokines. Additionally, H1N1 inoculation increased the TNF-α and CXCL1 mRNA 
expression in MLE-12 cells (a SV40-transformed murine lung epithelial cell line) directly; simultaneous 
rhTRX-1 treatment almost abolished this effect. The in vivo and in vitro experimentally obtained results 
indicate that rhTRX-1 treatment attenuates the increase in cytokine expression and secretion in the lung of 
H1N1-inoculated mice. 
Evaluating oxidative stress status in the experimental animals was crucial because the redox imbalance 
was regarded as a key lung injury pathway in influenza pneumonia (4, 8-14, 18). The DNA base-modified 
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product 8-OHdG is a marker for oxidative stress in tissue samples (6, 22, 36). In the present study, 8-OHdG 
formation was intense in the lung of H1N1-inoculated control mice; 8-OHdG was detected in infiltrating 
inflammatory cells and lung epithelial cells. Serum concentration of hydroperoxides is a marker for oxidative 
stress in the whole body (24, 25). A significant increase in serum hydroperoxides occurred in 
H1N1-inoculated mice, implying the presence of systemic oxidative stress enhancement. The rhTRX-1 
treatment suppressed 8-OHdG formation in the lung and serum concentration of hydroperoxides in 
H1N1-inoculated mice. These results indicate that oxidative stress enhancement is indeed involved in the 
inflammatory process of H1N1-induced pneumonia and that the protective effects of rhTRX-1 are partly 
attributed to its potent antioxidative action. 
In our murine model, influenza pneumonia is characterized histologically by intense infiltration of 
inflammatory cells (mainly neutrophils). Activated neutrophils, macrophages, and respiratory tract epithelial 
cells might release excess amounts of bioactive substances, including cytokines/chemokines, ROS, and tissue 
degradative enzymes and induce acute lung inflammatory disease (4, 5). Presumably, oxidative injury by the 
inflamed cells is targeted to the vascular endothelium, leading to lung edema and hemorrhage. Based on 
these considerations, it is plausible that rhTRX-1 administration ameliorates the lethal effects of influenza A 
virus (H1N1)-induced pneumonia in mice through antioxidative and anti-inflammatory actions, including the 
antichemotactic effect for neutrophils. 
For potential clinical use, we also examined whether treatment with rhTRX-1 after H1N1 inoculation is 
efficacious for protection. As a therapeutic protocol, vehicle or rhTRX-1 (40 μg) was given intraperitoneally 
to mice every second day from 30 min after inoculation (Day 0) to Day 12. Administration of rhTRX-1 
started 30 min after H1N1 inoculation exerted a significant survival-promoting effect. Therefore, it is 
conceivable that rhTRX-1 provided 30 min after virus inoculation ameliorated H1N1-induced lung 
inflammatory injury in mice. However, administration of rhTRX-1 started 4 hr after virus inoculation had no 
such therapeutic effect. 
The beneficial effects on H1N1-inoculated mice observed in this study might not be specific to rhTRX-1, 
but to the other antioxidative agents. The effects of a well-known glutathione precursor, N-acetylcysteine 
(41), on H1N1-induced pneumonia have been evaluated. The vehicle (100-μl PBS) or N-acetylcysteine (200 
mg/kg in 100-μl PBS (42)) was administered intraperitoneally to another group of 9-week-old mice every 
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second day from Day -1 to Day 13. With this intermediate dose, N-acetylcysteine did not alter the survival 
rate or lung injury score (at 72 hr) of H1N1-inoculated mice (data not shown). Results of previous studies 
have indicated that N-acetylcysteine has protective effects in the murine model of influenza pneumonia, 
especially when administered in combination with anti-viral drugs (4, 43, 44). N-acetylcysteine reportedly 
has beneficial effects in various clinical conditions characterized by glutathione deficiency or oxidative stress 
enhancement (41). It is therefore highly possible that higher doses of N-acetylcysteine can efficiently reduce 
the lethal effects of influenza virus infection in our experimental model. This issue deserves further 
examination. 
Our results raise the possibility that loss of TRX-1 function aggravates influenza virus-induced 
pneumonia, although complete TRX-1 deficiency results in early embryonic lethality (45). The cecal ligation 
and puncture septic murine model revealed that neutralization of endogenous TRX-1 impaired mice survival 
but that treatment with rhTRX-1 enhanced mice survival (30). Although extracellular TRX-1 concentrations 
were elevated in many oxidative and inflammatory disorders (27-30), plasma TRX-1 concentrations were 
persistently low in children with meningococcal septic shock, possibly because of a genetic predisposition 
(46). Plasma TRX-1 concentrations were lower in patients with neutropenia/sepsis than in patients with 
systemic inflammatory response syndrome/sepsis (47). Although speculative, the low TRX-1 condition 
might contribute to the devastating nature of sepsis. At present, no information related to the concentration of 
TRX-1 in blood or lung lavage fluid from patients with influenza pneumonia is available. 
We reported that endogenous TRX-1 expression was induced by natural substances including estrogen, 
prostaglandins and cyclic AMP, geranylgeranylacetone (an anti-ulcer drug derived from a natural plant 
constituent), and temocapril (a non-sulfhydryl-containing angiotensin-converting enzyme inhibitor) (48). We 
reported also that the cytoprotective action of TRX-1 was augmented after S-nitrosation (49). Moreover, 
concentrations of TRX-1 (mean: 268 ng/ml) and nitrite/nitrate (mean: 479 μmol/L) in early human milk were 
found to be about 10 times higher than those (mean: 20 ng/ml, 40 μmol/L, respectively) in blood of healthy 
adults (50, 51). The protective effects of such “TRX-1 inducers” or “TRX-1 donors” against infectious 
disorders, including influenza pneumonia, warrant further study. 
The present results suggest that systemic administration of rhTRX-1 can be clinically beneficial for 
ameliorating acute lung injury in influenza virus-infected mice. However, several concerns persist in terms of 
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clinical relevance. First, the experimentally obtained results for animals cannot be extrapolated directly to the 
medical arena. Second, the survival rate of rhTRX-treated virus-inoculated mice is not entirely satisfactory, 
although the rhTRX-1 treatment proved to exert lung protective effects in the mice. Last, the post-treatment 
experiments suggest that the therapeutic time window for rhTRX-1 might be narrow. The combination of 
rhTRX-1 with current anti-influenza drugs might expand the therapeutic window as well as the protective 
effects of rhTRX-1 against influenza infection. Further investigations are necessary to explore the future 
clinical application of rhTRX-1 for severe influenza pneumonia in humans. 
 
CONCLUSIONS 
Exogenous administration of redox-active protein rhTRX-1 significantly improved the survival rate and 
attenuated lung histological changes in the murine model of influenza pneumonia. The rhTRX-1 treatment 
did not affect virus propagation in the animal lung. The protective mechanism of rhTRX-1 might be 
explained by its potent antioxidative and anti-inflammatory actions. These results suggest that rhTRX-1 
represents a possible pharmacological strategy for severe influenza virus infection in humans. 
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FIGURE LEGENDS 
Figure 1. Thioredoxin-1 mRNA expression in mice. 
A. Regional distribution of thioredoxin (TRX)-1 mRNA expression. Data are expressed as a percentage 
relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA and represent the mean (SE) of 
5-10 independent experiments. *p < 0.05 vs. brain, kidney, and spleen by one-way ANOVA with 
Bonferroni’s post-test. 
B. Changes of TRX-1 mRNA expression in the lung after rhTRX-1 administration. Data are expressed as a 
percentage relative to GAPDH mRNA and represent the mean (SE) of 3-5 independent experiments. *p < 
0.05 vs. 0 hr by one-way ANOVA with Bonferroni’s post-test. 
 
Figure 2. Effects of recombinant human thioredoxin-1 treatment on survival rate and viral load in the 
lung after H1N1 inoculation. 
A. Survival rate. All mice in the vehicle group (10 mice, broken line) died from Day 7 to Day 9. In the 
thioredoxin (TRX)-1 group (10 mice, solid line), 4 (40%) survived until Day 14. *p < 0.05 vs. vehicle. 
B. Viral load in the lung. Data represent the mean (SE) of 5 independent experiments. *p < 0.01 vs. 24 hr, 
120 hr by one-way ANOVA with Bonferroni’s post-test. Two-way ANOVA was significant for time, p < 
0.001; but not for treatment or time x treatment. No significant difference was detected between the two 
groups at any time point by Bonferroni’s post-test. 
 
Figure 3. Effects of recombinant human thioredoxin-1 treatment on lung histology after H1N1 
inoculation. 
A. Photomicrographs of lung tissue samples stained with hematoxylin and eosin at 72 hr after H1N1 
inoculation. They are representative of 5 independent experiments. (a) Vehicle-group lung tissue showed 
diffuse alveolar and interstitial edema, inflammatory cellular infiltration, hemorrhage, and bronchiolitis. (b) 
In thioredoxin (TRX)-1 group lung tissue, these features were much less severe. Original magnification, x 
200. 
B. Lung injury scores. Lung histological changes were graded from 0 to 4 in 4 categories. Lung injury scores 
were calculated by adding the individual grades for each category. Data represent the mean (SE) of 5 
independent experiments. Two-way ANOVA was significant for time, p < 0.001; treatment, p < 0.001; but 
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not for time x treatment. *p < 0.01 vs. vehicle by Bonferroni’s post-test. 
 
Figure 4. Effects of recombinant human thioredoxin-1 treatment on neutrophil infiltration in the lung 
after H1N1 inoculation. 
A. Neutrophil numbers in lung lavage fluid. Thioredoxin (TRX)-1 treatment significantly decreased the 
neutrophil number in lung lavage fluid at 24 hr and 72 hr after H1N1 inoculation. Data represent the mean 
(SE) of 5 independent experiments. Two-way ANOVA was significant for time, p < 0.005; treatment, p < 
0.001; but not for time x treatment. *p < 0.05 vs. vehicle by Bonferroni’s post-test. 
B. Photomicrographs of lung tissue samples stained with granulocyte-differentiation antigen (Gr-1) at 72 hr 
after H1N1 inoculation. They are representative of 3 independent experiments: (a) No H1N1 inoculation; (b) 
H1N1 inoculation, no primary antibody; (c) H1N1 inoculation, vehicle group; and (d) H1N1 inoculation, 
TRX-1 group. Arrowheads indicate positively stained (brown) cells. Scale bars, 100 μm. 
 
Figure 5. Effects of recombinant human thioredoxin-1 treatment on cytokine production in the lung 
after H1N1 inoculation. 
A. TNF-α concentrations in lung lavage fluid. Data represent the mean (SE) of 5 independent experiments. 
Two-way ANOVA was significant for treatment, p < 0.05; time x treatment, p < 0.05; but not for time. *p < 
0.01 vs. vehicle by Bonferroni’s post-test. 
B. CXCL1 concentrations in lung lavage fluid. Data represent the mean (SE) of 5 independent experiments. 
Two-way ANOVA was significant for time, p < 0.001; treatment, p < 0.05; but not for time x treatment. *p < 
0.01 vs. vehicle by Bonferroni’s post-test. 
C, D. Cytokine concentrations in lung tissue samples. Data represent the mean (SE) of 5 independent 
experiments. *p < 0.01 vs. vehicle by unpaired t-test. 
 
Figure 6. Effects of recombinant human thioredoxin-1 treatment on oxidative stress markers after 
H1N1 inoculation. 
A. Photomicrographs of lung tissue samples stained with 8-hydroxy-2’-deoxyguanosine at 72 hr after H1N1 
inoculation. They are representative of 3 independent experiments: (a) No H1N1 inoculation; (b) H1N1 
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inoculation, no primary antibody; (c) H1N1 inoculation, vehicle group; and (d) H1N1 inoculation, 
thioredoxin (TRX)-1 group. Arrowheads indicate positively stained (brown) cells. Scale bars, 100 μm. 
B. Hydroperoxides in blood serum. Data represent the mean (SE) of 5 independent experiments. Two-way 
ANOVA was significant for time, p < 0.05; but not for treatment or time x treatment. *p < 0.05 vs. vehicle by 
Bonferroni’s post-test. 
 
Figure 7. Effects of recombinant human thioredoxin-1 treatment on cytokine mRNA expression in 
H1N1-inoculated lung epithelial cells (MLE-12). 
Cells were inoculated with H1N1 (at multiplicity of infection of 10) for 6 hr. They were not treated or were 
treated with thioredoxin (TRX)-1 simultaneously. Data are expressed as a percentage relative to the basal 
expression level. n = 4 per group. *p < 0.01 vs. no H1N1 inoculation (medium alone) by unpaired t-test, #p < 
0.001 vs. H1N1 inoculation, no TRX-1 treatment by one-way ANOVA with Bonferroni’s post-test. 
 
Figure 8. Therapeutic effects of recombinant human thioredoxin-1 treatment started 30 min or 4 hr 
after H1N1 inoculation on mouse survival rate. 
A. Thioredoxin (TRX)-1 treatment started 30 min after virus inoculation significantly improved the survival 
rate of H1N1-inoculated mice (14 mice per group). *p < 0.05 vs. vehicle. 
B. The TRX-1 treatment started 4 hr after inoculation had no effect on the survival rate (11 mice per group). 
AB
TRX-1/GAPDH
0
1
3
H
o
u
r
s
 
a
f
t
e
r
 
r
h
T
R
X
-
1
 
a
d
m
i
n
i
s
t
r
a
t
i
o
n
0
6
2
.
0
1
.
0
＊
＊
＊
1
.
0 0
2
.
0
TRX-1/GAPDH
TR
X
-
1
＊
Survival rate (%)
D
a
y
 
a
f
t
e
r
 
i
n
o
c
u
l
a
t
i
o
n
V
e
h
i
c
l
e
0
1
0
0
 
5
0
 
0
 
5
 
1
0
A B
6 5 4 3 2 1
H1N1 copies 
(×105)
V
e
h
i
c
l
e
T
R
X
-
1
＊
＊
7
2
4
7
2
1
2
0
H
o
u
r
s
 
a
f
t
e
r
 
i
n
o
c
u
l
a
t
i
o
n
0
A B
a
b
0
1
0
1
5
Lung injury score
5
＊
＊
V
e
h
i
c
l
e
T
R
X
-
1
2
4
7
2
1
2
0
H
o
u
r
s
 
a
f
t
e
r
 
i
n
o
c
u
l
a
t
i
o
n
＊
ab
c
d
Neutrophil number (×106)
3 2 14 0
2
4
7
2
1
2
0
V
e
h
i
c
l
e
T
R
X
-
1
＊
H
o
u
r
s
 
a
f
t
e
r
 
i
n
o
c
u
l
a
t
i
o
n
A B
＊
0100
(
p
g
/
m
g
 
l
u
n
g
)
200
Vehicle
TRX-1
C
X
C
L
1
 
72 hr after inoculation
＊
0
20
40
60 Vehicle
TRX-1
(
p
g
/
m
g
 
l
u
n
g
)
T
N
F
α
 
72 hr after inoculation
＊
0
200
C
X
C
L
1
 
(
p
g
/
m
l
)
400
Vehicle
TRX-1
Hours after inoculationHours after inoculation
0
T
N
F
α
 
(
p
g
/
m
l
)
10
0
30
0
40
0
24 72 120
Vehicle
TRX-1
＊
A B
C D
24 72 120
＊20
0
50
0
600
300
10
0
2
0
0
3
0
0
0
2
4
7
2
1
2
0
H
o
u
r
s
 
a
f
t
e
r
 
i
n
o
c
u
l
a
t
i
o
n
V
e
h
i
c
l
e
T
R
X
-
1
Hydroperoxides (CARR U)a
b
c
d
A B
＊
02 1
#
CXCL1 
Fold increase
#
＊
(
n
g
/
m
l
)
 
0
 
0
 
1
0
 
1
0
0
 
H
1
N
1
-
+
 
+
 
+
 
T
R
X
-
1
 
 
TNFα
Fold increase 04 3 2 1
#
#
T
R
X
-
1
 
 
(
n
g
/
m
l
)
 
0
 
0
 
1
0
 
1
0
0
 
H
1
N
1
 
 
-
+
 
+
 
+
 
＊
A B
TR
X
-
1
Survival rate (%)
D
a
y
 
a
f
t
e
r
 
i
n
o
c
u
l
a
t
i
o
n
V
e
h
i
c
l
e
0
1
0
0
 
5
0
 
0
 
5
 
1
0
T
R
X
-
1
Survival rate (%)
D
a
y
 
a
f
t
e
r
 
i
n
o
c
u
l
a
t
i
o
n
V
e
h
i
c
l
e
0
1
0
0
 
5
0
 
0
 
5
 
1
0
B
＊
A
